Audit: QRS - LSD Analogues for Health & Longevity

Audit conducted on 30/09/2026 06:39 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 94
Passed 86
Failed 0
N/A 8
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Protocol, time-to-effect, tier lists, gates, monitoring and at-a-glance facts all trace to ER lines 356-358, 391, 165-213, 240-302, 317-338, 408-428, 445-449
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious qualifiers kept (e.g. “no analogue has a trial-tested regimen”, “roughly equal in strength”, “have not clearly outperformed placebo”)
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No claim strengthened or softened; contraindications mirror ER line 330-338 wording
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications drawn from ER “Populations who should avoid”; interactions from ER interaction bullets; no modifying factor relabelled
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 Only James Fadiman named, as in ER line 358 for the same fact; no PMIDs, NCT IDs or brands
1.6 The QRS does not introduce new attributions. 🟢 No new attributions

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Mirrors the ER Conclusion framing (lines 445-451)
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Protocol and monitoring presented descriptively (“dosing deferred”, “reference regimen”)
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢  
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms carried from ER labels are glossed (ECG, echocardiogram, ALT, antidepressant classes)
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 It DOES NOT address the reader directly 🟢  
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 Uses “longevity”; no “anti-aging”
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 No colloquial route or event terms; lede plain wording mirrors ER Conclusion

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings, gate headings, tier labels and table headers unchanged
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 template spans present (verified by diff against template)
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Diff against template shows only variable spans, metadata values and display:none on empty tiers changed

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section feeding the QRS is empty; empty High/Medium tiers are governed by 12.5/13.5
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels and interaction labels use ER bold labels verbatim (ER lines 318-328, 356-358)
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Time-to-effect labels derive from ER wording (line 391, 189)
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators; ⚠️ Conflicted flags stripped
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed (parentheticals trimmed, rationale stripped); no page-break content

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment on line 2 directly after doctype
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 duration “00:00” quoted because it contains a colon
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.9.29 matches QRS.md version
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢  
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “LSD Analogues for Health & Longevity - Quick Reference Sheet”
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “LSD Analogues for Health & Longevity”
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0930-0615 → 09/30/2026
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Opus 5.5
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 No extra header content

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens with “chemical relatives of the mind-altering drug LSD sold as unregulated research chemicals” and its uses before the evidence verdict
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses ER Conclusion (appeal, evidence base, microdosing, main risks)
7.3 [at_a_glance] is no longer than 70 words 🟢 70 words (script count)
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each fact maps to ER lines 39-41, 381, 445-449
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms beyond the intervention name LSD
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years or sizes
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No effect sizes or statistics

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 From ER Key Interactions & Contraindications (lines 330-338)
8.2 [stop_items] represent the Contraindications from the ER 🟢 All 7 ER populations listed
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 No trailing explanations or dash clauses
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Thresholds and time windows (≥140/90 mmHg, 6 months, under 18, Child-Pugh Class C) preserved
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation in contraindications
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated; ER names populations to avoid
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not empty

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 From ER Key Interactions & Contraindications (lines 317-328)
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 11 interactions listed; lithium excluded as already a contraindication
9.3 Individual [caution_items] are formatted as <li></li> 🟢  
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Mechanisms and mitigations stripped
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists and caution/monitor severity preserved
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation in interactions
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Section populated; ER names interactions
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section is not empty

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 From ER Therapeutic Protocol (lines 356-358)
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Reference regimen, 1P-LSD equivalence and microdosing schedule
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three actionable aspects exist
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Anxiety improvement, longer sleep, acute effects (ER lines 191, 391)
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Anxiety (large effect) before sleep; acute effects last
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three time-to-effect aspects exist
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 From ER Expected Benefits
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 ER headings only; no effect sizes or qualifiers
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high and benefits_medium set to display: none

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 From ER Potential Risks & Side Effects
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 ER headings only; no frequencies
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_high and risks_medium set to display: none

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 From ER Monitoring Protocol & Defining Success
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 8 ER table biomarkers listed
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Cadence reflects ER line 408

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 From ER qualitative markers (lines 421-428)
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All 6 qualitative markers listed

Issues 30/09/2026 06:39

Pass rate 100.00%. No issues found.

Issues 30/09/2026 06:35

  1. 7.2 — Microdosing verdict missing from summary: The at_a_glance text (line 433) omits the ER Conclusion’s execution-relevant point that “Small, repeated doses have not clearly outperformed placebo in careful studies” (ER line 447), while still citing healthy-ageing interest that rests largely on microdosing.

Fixes 30/09/2026 06:35

  1. 7.2 — Microdosing verdict added to summary: Rewrote at_a_glance to add the ER Conclusion point that small repeated doses have not clearly outperformed placebo, and tightened the other wording to stay within 70 words.

Issues 30/09/2026 06:32

  1. 1.1 — 1P-LSD dose equivalence misstated: action_2_value (line 458) “100 µg 1P-LSD ≈ 70 µg LSD” reads as a 70 µg dose equivalence, whereas the ER says 100 µg 1P-LSD “contains about 70 µg LSD by molecular weight” and users treat it as “roughly equipotent to LSD”.
  2. 1.3 — Psychosis qualifier dropped in lede: at_a_glance (line 433) says “rare lasting loss of touch with reality” without the ER Conclusion qualifier “in vulnerable people” (ER line 449).
  3. 7.4 — Analogues overgeneralized as mind-altering: at_a_glance (line 433) calls all analogues “mind-altering compounds”, while the ER reserves that for LSD and includes versions “built to avoid hallucinations” (ER lines 39, 445).

Fixes 30/09/2026 06:32

  1. 1.1 — 1P-LSD dose equivalence corrected: Changed action_2_value from “100 µg 1P-LSD ≈ 70 µg LSD” to “100 µg 1P-LSD contains ≈70 µg LSD”, matching the ER’s molecular-weight statement.
  2. 1.3 — Psychosis qualifier restored: Changed at_a_glance “rare lasting loss of touch with reality” to “rare lasting loss of touch with reality in vulnerable people”, per the ER Conclusion.
  3. 7.4 — Lede no longer overgeneralizes: Replaced “mind-altering compounds closely related to LSD” with “close chemical relatives of the mind-altering compound LSD” and tightened wording to stay at 70 words.

Issues 30/09/2026 06:30

  1. 2.7 — Pharmacology jargon in protocol: The 1P-LSD dose-equivalence sub-line (action_2_sub, line 461) says “users treat it as roughly equipotent to LSD”; “equipotent” is specialist jargon with a plain-language equivalent.

Fixes 30/09/2026 06:30

  1. 2.7 — Pharmacology jargon in protocol: Replaced “roughly equipotent to LSD” with “roughly equal in strength to LSD” in the 1P-LSD dose-equivalence sub-line (action_2_sub).

Issues 30/09/2026 06:27

  1. 2.7 — Receptor jargon in Monitoring: marker_4_why (QRS line 646) reads “Serotonin 2B valve risk”, receptor-subtype jargon where the plain “heart valve risk” used in the ER (lines 298, 348) conveys the same fact.

Fixes 30/09/2026 06:27

  1. 2.7 — Receptor jargon in Monitoring: Changed marker_4_why from “Serotonin 2B valve risk” to “Heart valve risk”.

Issues 30/09/2026 06:23

  1. 1.3 — Dropped “mostly” hedge: At-A-Glance (line 433) states the appeal “rests on supervised trials of LSD itself”, while the ER Conclusion says it “rests mostly on trial evidence for LSD itself”, strengthening the claim.
  2. 2.5 — Imperative dosing advice: Monitoring targets at lines 610 and 621 read “defer dosing at ≥140/90 mmHg” and “defer dosing if >100”, phrasing thresholds as advice rather than presenting information.
  3. 2.15 — Consumer-grade “reactions” wording: At-A-Glance (line 433) uses “dangerous reactions with lithium” instead of formal terminology such as “interactions”.

Fixes 30/09/2026 06:23

  1. 1.3 — Restored “mostly” hedge: Changed At-A-Glance “rests on supervised trials of LSD itself” to “rests mostly on supervised trials of LSD itself”, matching the ER Conclusion.
  2. 2.5 — Imperative dosing advice removed: Changed Monitoring targets “defer dosing at ≥140/90 mmHg” / “defer dosing if >100” to “dosing deferred at ≥140/90 mmHg” / “dosing deferred if >100”.
  3. 2.15 — Formal interaction terminology: Changed At-A-Glance “dangerous reactions with lithium” to “dangerous lithium interactions” (lede stays at 70 words).

Issues 30/09/2026 06:21

  1. 12.3 / 12.4 — Benefit qualifier not stripped: benefits_low (line 528) keeps the parenthetical qualifier “(evidence conflicted)” on “better everyday mood, focus and cognition from microdosing”.
  2. 13.3 / 13.4 — Risk qualifiers not stripped: risks_low (line 585) keeps “(evidence conflicted)” and adds qualifiers absent from the ER headings (“seed-derived” LSA, “non-hallucinogenic” 2-Br-LSD).

Fixes 30/09/2026 06:21

  1. 12.3 / 12.4 — Benefit qualifier stripped: Removed “(evidence conflicted)” from the microdosing item in benefits_low.
  2. 13.3 / 13.4 — Risk qualifiers stripped: In risks_low, changed “with seed-derived LSA” to “with LSA” and “psychoactive effects of non-hallucinogenic 2-Br-LSD (evidence conflicted)” to “psychoactive effects of 2-Br-LSD”, matching the ER headings.

Issues 30/09/2026 06:18

  1. 1.3 — Salt-form qualifier dropped: action_2 (lines 458–461) gives “100 µg 1P-LSD ≈ 70 µg LSD” without the ER’s qualifier “in its usual salt form” (ER line 357), generalising the equivalence.
  2. 2.7 — Unexplained compound abbreviations: risks_low (line 585) names “LSA” and “2-Br-LSD” with no indication anywhere on the sheet of what these compounds are, leaving the two risk items opaque to non-specialists.
  3. 11.2 — Time-to-effect order wrong: time_2 “Acute effects” (lines 494–500) has no related benefit but is placed above time_3 “Longer sleep” (lines 505–511), which ties to a quantified ER benefit.

Fixes 30/09/2026 06:18

  1. 1.3 — Salt-form qualifier restored: action_2_sub changed from “By molecular weight; …” to “In its usual salt form, by molecular weight; …”, matching ER line 357.
  2. 2.7 — Compound abbreviations clarified: In risks_low, “with LSA” became “with seed-derived LSA” and “psychoactive effects of 2-Br-LSD” became “psychoactive effects of non-hallucinogenic 2-Br-LSD”, using the ER’s own descriptors.
  3. 11.2 — Time-to-effect order corrected: Swapped time_2 and time_3 so “Longer sleep” (a quantified benefit) now precedes “Acute effects”.